Health Canada approves new indication for lung cancer treatment option ALUNBRIG®
Takeda Canada Celebrates Resilient Rare Stars on Rare Disease Day
Rute Fernandes Appointed General Manager of Takeda Canada
Takeda Applies to Cease being a Reporting Issuer in Canada
Ready-to-use self-injectable formulation of ENTYVIO® (vedolizumab) now available for Canadians for the maintenance treatment of moderately to severely active Crohn’s disease and ulcerative colitis
